Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

NCT05124561 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The trial protocol was not approved by the regulatory authorities.

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
BIOLOGICAL: Placebo

Sponsor

CanSino Biologics Inc.

Collaborators

[object Object]